Press Release : Roche's Tecentriq approved by -2-

   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2020 employed more than 100,000 people worldwide. 
In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 
58.3 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit www.roche.com. 
 
   *High programmed death ligand-1 (PD-L1) expression in the indication 
statement is defined as PD-L1 stained >=50% of tumour cells (TC) [TC 
>=50%] or PD-L1 stained tumour-infiltrating cells (IC) covering >=10% of 
the tumour area [IC >=10%]. PD-L1 staining is the process by which the 
PD-L1 protein is visualised during testing. 
 
   All trademarks used or mentioned in this release are protected by law. 
 
   References 
 
   [1] Herbst RS, et al. Atezolizumab for first-line treatment of 
PD-L1-selected patients with NSCLC. N Engl J Med 2020:383:1328--39. 
 
   [2] Supplement to: Herbst RS, et al. Atezolizumab for first-line 
treatment of PD-L1-selected patients with NSCLC. N Engl J Med 
2020;383:1328--39. 
 
   [3] Herbst RS, et al. IMpower110: updated OS analysis of atezolizumab vs 
platinum-based chemotherapy as first-line treatment in PD-L1--selected 
NSCLC [WCLC 2020 Poster FP13.03]. 
 
   [4] World Health Organization: GLOBOCAN 2020 -- Lung Cancer: Estimated 
cancer incidence, mortality and prevalence worldwide. [Internet; cited 
March 2021] Available from: 
https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. 
 
 
   [5] American Cancer Society: What Is Lung Cancer? [Internet; cited March 
2021]: Available from: 
https://www.cancer.org/cancer/lung-cancer/about/what-is.html. 
 
   Roche Group Media Relations 
 
   Phone: [phone] / e-mail: [e-mail] 
https://www.globenewswire.com/Tracker?data=TYXKox3bKJCZBhvgCo3ueQFwVW9fee4r4W3daOf0o6X7m94Vyk4TRogEJ1027o2XxScUq9jTp-H-dw5SqboKJKdO7bVLhc_VSzyvNgso5iTWjsROPvCmbXz_cWG9fhW9 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein 
 Phone: [phone] 
 
 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                        Jon Kaspar Bayard 
 Phone: [phone]                 Phone: [phone] 
 e-mail: [e-mail]          e-mail: [e-mail] 
Dr. Sabine Borngräber             Dr. Bruno Eschli 
 Phone: [phone]                 Phone: [phone] 
 e-mail: [e-mail]   e-mail: [e-mail] 
Dr. Birgit Masjost                     Dr. Gerard Tobin 
 Phone: [phone]                 Phone: [phone] 
 e-mail: [e-mail]       e-mail: [e-mail] 
 
Investor Relations North America 
Loren Kalm                             Dr. Lisa Tuomi 
 Phone: [phone]                 Phone: [phone] 
 e-mail: [e-mail]            e-mail: [e-mail] 
 
 
 
 
   Attachment 
 
 
   -- 05052021_MR_IMpower110 EMA approval _en 
      https://ml-eu.globenewswire.com/Resource/Download/519d499c-58c1-49da-9504-2d688a19d974

(END) Dow Jones Newswires

May 05, 2021 01:00 ET (05:00 GMT)